Enanta Pharma (ENTA) Reports Q2 EPS of $1.49

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of $1.49, may note compare to the analyst estimate of $1.76. Revenue for the quarter came in at $57.4 million versus the consensus estimate of $63.4 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
• Energy Fuels to acquire rare earth magnet maker VAC for $1.9 billion